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A B S T R A C T
Background: Alcohol and tobacco use are heritable phenotypes. However, only a small number of common
genetic variants have been identiﬁed, and common variants account for a modest proportion of the heritability.
Therefore, this study aims to investigate the role of low-frequency and rare variants in alcohol and tobacco use.
Methods: We meta-analyzed ExomeChip association results from eight discovery cohorts and included 12,466
subjects and 7432 smokers in the analysis of alcohol consumption and tobacco use, respectively. The ExomeChip
interrogates low-frequency and rare exonic variants, and in addition a small pool of common variants. We
investigated top variants in an independent sample in which ICD-9 diagnoses of “alcoholism” (N=25,508) and
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Pathway analysis “tobacco use disorder” (N=27,068) had been assessed. In addition to the single variant analysis, we performed
gene-based, polygenic risk score (PRS), and pathway analyses.
Results: The meta-analysis did not yield exome-wide signiﬁcant results. When we jointly analyzed our top results
with the independent sample, no low-frequency or rare variants reached signiﬁcance for alcohol consumption or
tobacco use. However, two common variants that were present on the ExomeChip, rs16969968
(p=2.39× 10−7) and rs8034191 (p=6.31×10−7) located in CHRNA5 and AGPHD1 at 15q25.1, showed
evidence for association with tobacco use.
Discussion: Low-frequency and rare exonic variants with large eﬀects do not play a major role in alcohol and
tobacco use, nor does the aggregate eﬀect of ExomeChip variants. However, our results conﬁrmed the role of the
CHRNA5-CHRNA3-CHRNB4 cluster of nicotinic acetylcholine receptor subunit genes in tobacco use.
1. Introduction
Alcohol and tobacco use belong to the world’s leading health risks
and are responsible for the premature death of 3.3 million and 6 million
people each year, respectively (World Health Organization, 2014;
World Health Organization, 2015). Overall 5.1% of the global burden of
disease and injury, measured in disability-adjusted life years (DALYs), is
attributable to alcohol, and 3.7% is attributable to smoking (World
Health Organization, 2009, 2014). Alcohol and tobacco use initiation
and severity are inﬂuenced by a combination of genetic and environ-
mental risk factors. Examples of environmental exposures that impact
on substance use outcomes are social stress, traumatic life events, peer
pressure, inadequate parenting, insuﬃcient social control, and low
socio-economic status (De Bellis and Zisk, 2014; Kendler et al., 2011;
Lijﬃjt et al., 2014; Loke and Mak, 2013; Van Ryzin et al., 2012; Young-
Wolﬀ et al., 2011). Heritability estimates (i.e., the proportion of phe-
notypic variance attributable to genetic variance) of 40–60% and
45–86% (Broms et al., 2006; Mbarek et al., 2015; Verhulst et al., 2015;
Vink et al., 2005) for alcohol and tobacco use-related traits, respec-
tively, indicate a strong genetic component inﬂuencing these behaviors.
Elucidating which genetic variants contribute to alcohol and tobacco
use is an important step in unraveling the underlying biological me-
chanisms. Although current pharmacological treatments for alcohol and
tobacco use disorders have demonstrated positive treatment outcome,
the eﬀects are moderate at best, and many patients do not beneﬁt from
these treatments (Goh and Morgan, 2017; Stead and Lancaster, 2012).
An improved understanding of the biological mechanisms will aid the
development of novel medications and prevention methods for sub-
stance use-related problems.
Various methods have been applied to identify genetic variants as-
sociated with substance use. During the last decade, Genome-Wide
Association Studies (GWAS) have been the preferred study design due
to the capacity to study single nucleotide polymorphisms (SNPs) in a
genome-wide manner without the need for a priori hypotheses. GWAS
usually captures common variants (i.e., variants with a minor allele
frequency (MAF) larger than 5% in the population), but recent large-
scale GWAS also included low-frequency variants (MAF 1–5%) and
even variants that occur in 0.1% of the population.
The latest GWAS for alcohol consumption comprised 112,117 in-
dividuals and identiﬁed 14 signiﬁcant loci (Clarke et al., 2017), in-
cluding variants in the gene KLB, which had been identiﬁed previously
by Schumann et al. (2016). The gene product of KLB, β-klotho, controls
alcohol use in mice (Schumann et al., 2016). Other signiﬁcant loci were
found in the alcohol dehydrogenase (ADH) gene cluster, which has
consistently been associated with alcohol consumption (Gelernter et al.,
2014; Macgregor et al., 2009). SNPs identiﬁed in these genes alter al-
cohol metabolism (Harada et al., 1983; Thomasson et al., 1991; Yoshida
et al., 1991). Furthermore, the authors reported multiple gene-based
associations including DRD2, encoding a dopamine receptor, and
PDE4B, which plays a role in signal transduction.
For tobacco use, SNPs located at the chromosomal region 15q25.1,
which includes the CHRNA5-CHRNA3-CHRNB4 cluster of nicotinic
acetylcholine receptor subunit genes, show the most robust associations
(David et al., 2012; Liu et al., 2010; Saccone et al., 2010a; Tobacco and
Genetics, 2010). Other genes implicated in tobacco use are HECTD2-
AS1 (LOC100188947), EGLN2, BDNF, and DBH (Tobacco and Genetics,
2010). Although the identiﬁed loci and genes for tobacco use are dif-
ferent from alcohol consumption, twin studies suggest that some pro-
portion of the heritability of alcohol and tobacco use is shared between
the two traits (Koopmans et al., 1997).
Individual SNPs identiﬁed by GWAS explain only a modest pro-
portion of the variation in complex traits (Manolio et al., 2009). In
addition, the aggregate eﬀect of all SNPs included in a GWAS does not
fully capture the family-based heritability of traits. For alcohol con-
sumption and tobacco use, GWAS SNPs generally capture less than 50%
of the twin-based heritability (Lubke et al., 2012; Mbarek et al., 2015;
Vrieze et al., 2013). The proportion of the genetic liability which has
not yet been explained by the studied common variants is referred to as
“the missing heritability” (Manolio et al., 2009). Part of the missing
heritability may be explained by gene-environment (GxE) interaction,
structural variants, and epistasis. Furthermore, rare genetic variation
(MAF<0.01), which is not captured in conventional GWAS arrays,
may contribute substantially to the heritability of complex traits (Speed
et al., 2017).
Genome-wide interrogations of rare variants that contribute to al-
cohol and tobacco use are scarce. Studies that instead investigated the
role of rare variants in a limited number of candidate genes showed
signiﬁcant associations with substance dependence. For example, var-
iants within the gene CHRNB3 are associated with alcohol dependence
(Haller et al., 2014) while rare variants in the genes CHRNB4, NRXN1,
CHRNA9, TAS2R38, CHRNA2, NTRK2, GABBR2, GRIN3A, DNM1, DBH,
NRXN2, ANKK1/DRD2, NRXN3, CDH13, and ARRB2 were shown to
inﬂuence the risk of nicotine dependence (Haller et al., 2012; Yang
et al., 2015). However, the associations of these rare variants with al-
cohol and nicotine dependence have not been replicated, and are
therefore suggestive in nature. The relevance of investigating rare
variants is further demonstrated by an observed inverse relationship
between a variant’s eﬀect size and its frequency in the population (Park
et al., 2011). This relationship indicates that a genome-wide explora-
tion of the impact of rare genetic variants may provide additional in-
sights into the genetic etiology of substance use phenotypes.
The introduction of the Illumina Inﬁnium HumanExome BeadChip
array (Illumina Inc., San Diego, CA) enabled the study of rare genetic
variants in a genome-wide and cost-eﬀective way (Cirulli and
Goldstein, 2010; Grove et al., 2013; Lee et al., 2014; Vrieze et al.,
2014). The “ExomeChip” contains a dense amount of low-frequency
and rare nonsynonymous SNPs, and an additional smaller set of
common SNPs that aid quality control of the genotypes. The non-
synonymous SNPs change the protein sequence by coding for diﬀerent
amino acids. Their interrogation facilitates functional interpretation of
causal variants or genes due to a clear mechanism through which they
exert their eﬀect on traits and diseases. Combined with potentially large
eﬀect sizes, rare nonsynonymous SNPs are attractive drug targets. For
alcohol and nicotine dependence, a single ExomeChip study has been
conducted in 7181 individuals. No signiﬁcant SNP or gene associations
were detected, probably due to the limited sample size (Vrieze et al.,
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2014).
The current study seeks to increase our knowledge on the role of
rare exonic variants in alcohol and tobacco use and to improve our
understanding of the biological mechanisms underlying these pheno-
types. In a genome-wide meta-analysis, we aggregated the genetic as-
sociation results for alcohol and tobacco use from eight Dutch cohorts
(Brandsma et al., 2012). The discovery sample includes 12,466 in-
dividuals for alcohol consumption and 7432 for tobacco use, which
makes it the largest study of its kind to date. In addition, we tested our
top ﬁndings in a case-control replication sample including 25,508 in-
dividuals for tobacco use disorder and 27,068 individuals for alco-
holism. The aims of this study are: i) to investigate the association of
rare exonic variants with alcohol consumption and tobacco use; ii) to
investigate the aggregate eﬀect of multiple rare variants within genes
using gene-based tests; iii) to investigate pathways involved in alcohol
consumption and tobacco use by performing gene-set analyses; and iv)
to investigate the proportion of the total phenotypic variance in alcohol
consumption and tobacco use explained by common and rare variants
using Polygenic Risk Score (PRS) analysis.
2. Methods
2.1. Participants
The discovery sample included eight Dutch cohorts which were all
part of the Biobanking and Biomolecular Research Infrastructure for
The Netherlands (BBMRI-NL) (Brandsma et al., 2012). The total sample,
after genotype quality control (see below), consisted of 12,466 subjects
for alcohol consumption and 7432 subjects for tobacco use, the sample
contains both males and females. Only subjects between 18 and 85
years old were included. Detailed information about the individual
cohorts can be found in Supplementary information section 2.
The replication sample consisted of a single cohort from BioVU:
Vanderbilt University’s DNA biobank (Roden et al., 2008). Top SNPs for
alcohol consumption were replicated using data from 367 cases with an
ICD-9 diagnosis of “Alcoholism” and 25,141 controls. Top SNPs for
tobacco use were replicated using data from 1927 cases with an ICD-9
diagnosis of “Tobacco use disorder” and 25,141 controls. Subjects were
between 13 and 90 years old. Detailed information about the replica-
tion cohort can be found in Supplementary information section 2.
2.2. Phenotypes
Alcohol consumption and tobacco use were assessed with self-re-
ports in the discovery cohorts. Alcohol consumption was deﬁned as the
number of standard alcoholic drinks per week. Tobacco use was deﬁned
by the number of cigarettes smoked per day (CPD) in current and past
smokers (i.e., ever-smokers). Subjects who smoked fewer than 100 ci-
garettes during their life were not included in the analyses (i.e., “non-
smokers”). To diminish the eﬀect of outliers due to the skewed nature of
the phenotype data, logarithmic transformations were performed.
Detailed information about the phenotypes and their recruitment can
be found in Supplementary Table 1 and Supplementary Sections 2 and
3. The phenotypes “Tobacco use disorder” and “Alcoholism”, from the
independent replication sample BioVU, were assessed with the
International Classiﬁcation of Diseases, Ninth Revision (ICD-9 codes).
2.3. Genotypes
All individuals of the discovery cohorts, as well as the replication
cohort, were genotyped using the Illumina Human Exome BeadChip
(Illumina inc., San Diego, CA). This ExomeChip interrogates 247,870
markers, and mainly includes low-frequency and rare variants (i.e.,
90% of the variants had a MAF lower than 5%) (Grove et al., 2013). The
remaining variants are common to aid in the genotype quality control.
Detailed information about the speciﬁcations of the Illumina Inﬁnium
Exome-24 v1.1 BeadChip can be found in Supplementary Table 2.
Genotype intensities for the discovery samples were called with Geno-
meStudio and zCall to obtain genotype data. Initially, we used Geno-
meStudio (i.e., GenCall) for common variant calling and for the ex-
clusion of individuals with low quality genotypes (Grove et al., 2013;
Guo et al., 2014). Subsequently, we used zCall to call rare variants
(Goldstein et al., 2012). The genotype intensities for the replication
cohort were called with Genotyping module v1.9.4 from GenomeStudio
v2011.1.
2.4. Quality control of genotype data
Quality control (QC) was performed using PLINK (Purcell et al.,
2007). Each discovery cohort used the same analysis plan for QC in
order to reach consistency (see Supplementary information section 3).
We included only autosomal variants in the analysis. Individuals with
≥5% missingness and SNPs with ≥5% missingness were excluded, as
well as individuals with ambiguous sex information and a hetero-
zygosity rate outside the 0.35–0.45 range. In non-family based cohorts,
one of each pair of individuals who were related (pihat> 0.2) were
excluded. In addition, based on multidimensional scaling (MDS) and
1000 Genomes data (Abecasis et al., 2012), all non-Caucasian subjects
were excluded. All SNPs with a minor allele count (MAC) of< 5 were
removed. Finally, when combining the eight discovery cohorts, SNPs
which deviated from HWE with a p-value larger than 1.0× 10−5 and a
call rate lower than 0.95 were excluded. A detailed overview of the QC
per cohort can be found in Supplementary Table 3 and Supplementary
information section 3. An overview of the remaining number of subjects
and SNPs after QC by cohort can be found in Supplementary Table 3.
The QC of the replication sample was performed using PLINK 1.9
(Chang et al., 2015), and followed the recommendation of Guo et al.
(2014).
2.5. Single-variant and gene-based analyses
For each discovery cohort, association analyses were performed
using a linear regression model in RVTESTS (Zhan et al., 2016), in
which the inverse normal transformed trait residuals were analyzed.
Ten principal components were included as covariates to control for
population stratiﬁcation. In family-based cohorts, relatedness was ac-
counted for using the kinship matrix in RVTESTS (Lippert et al., 2011;
Zhan et al., 2016). The association analysis on the independent re-
plication sample was conducted using PLINK 1.9, using either a Fisher's
exact test for SNPs with a MAF < 1% and a logistic regression for all
SNPs with a MAF ≥1%.
To combine the association results of the individual discovery co-
horts, we meta-analyzed the results with the software package RARE-
METAL (Feng et al., 2014). The meta-analysis was performed using the
single variant score statistics of each cohort, which summarize evidence
for association, together with the covariance matrix, which summarizes
linkage disequilibrium relationships among variants. To determine
signiﬁcance for the single-variant analyses, a Bonferroni correction for
the number of SNPs tested was used. Due to the exclusion of SNPs with
a MAC lower than 5, fewer SNPs were tested in the CPD sample than in
the alcohol consumption sample, since the CPD sample included fewer
subjects. For alcohol consumption and CPD, the Bonferroni corrected
signiﬁcance thresholds were set at 6.33× 10−7 and 7.29×10−7, re-
spectively.
In addition to single-variant analysis, we performed gene-based tests
using the sequence kernel association test (SKAT) (Wu et al., 2011). The
signiﬁcance threshold for the SKAT was determined by a Bonferroni
correction for the number of genes tested; the thresholds for alcohol
consumption and CPD were 5.02×10−6 and 5.75×10−6, respec-
tively. In the CPD sample fewer genes were tested than in the alcohol
consumption sample, since the CPD sample included fewer SNPs, as
explained in the preceding paragraph. The gene-based tests included
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only variants with a MAF<5%, and genes that contained two variants
or more.
2.6. Joint analyses of single variants with an independent replication sample
To examine the robustness of our top ﬁndings, we also tested their
association in BioVU (Roden et al., 2008). For the top 10 SNPs (i.e.,
SNPs with lowest p-values) that we identiﬁed, we performed an asso-
ciation analysis in PLINK (Purcell et al., 2007) using “Tobacco use
disorder” and “Alcoholism” of ICD-9 codes. Following the re-
commendations of Skol et al. (2006) (Skol et al., 2006), we meta-ana-
lyzed these results with our discovery meta-analysis using the weighted
Z-score method of METAL (Willer et al., 2010). Signiﬁcance was de-
termined using the Bonferroni corrected threshold from the discovery
analysis (6.33×10-7 for alcohol consumption and 7.29×10-7 for
CPD). We used the eﬀective sample sizes to weight the BioVU samples,
which were 1447 and 7159 individuals for Alcoholism and Tobacco use
disorder, respectively (calculated using the following formula:
((4×number of cases× number of controls)/(number of
cases+ number of controls)), as recommended by the Broad Institute’s
Ricopili pipeline).
2.7. Pathway analysis
We investigated whether pathways related to alcohol and nicotine
addiction were associated with alcohol consumption and CPD by per-
forming a gene-set analysis in MAGMA (de Leeuw et al., 2015). We
tested two Gene Ontology (GO) pathways, namely the ‘response to ni-
cotine’ and the ‘response to ethanol’ (Gene Ontology Consortium,
2015). The gene-based p-values obtained in the SKAT analyses were
used as input. We performed competitive gene-set analyses which test
whether the genes in the gene-set are more strongly associated with the
phenotype of interest than the other genes included in our genotype
data (n= 13,413). Our dataset enabled us to test 84 genes from the
‘response to ethanol’ and 36 from the ‘response to nicotine’ pathways.
The associations were corrected for dependencies between genes (with
a gene correlation matrix based on the ExomeChip SNPs) and con-
founding eﬀects of gene size and gene density.
2.8. Polygenic risk score analysis
To determine whether ExomeChip variants explain a signiﬁcant
proportion of the phenotypic variance when aggregated, we performed
a PRS analysis for alcohol consumption and CPD using PRSice (Euesden
et al., 2015). The PRS is an individual-level score that is calculated
based on the number of risk variants that a person carries, weighted by
SNP eﬀect sizes that are derived from an independent large-scale dis-
covery GWAS. As such, the score is an indication of the total genetic risk
of a speciﬁc individual for a particular trait, and can be used to estimate
genetic overlap between traits (Dudbridge, 2013; Smoller, 2013;
Stringer et al., 2014).
We split our total sample of eight cohorts between a discovery (or
training) sample and a target sample. The discovery sample consisted of
data from seven BBMRI-NL cohorts, ensuring a suﬃciently large sample
to detect SNP eﬀects for alcohol consumption and CPD. The remaining
BBMRI-NL cohort (UHP), which was the second largest sample out of
the eight cohorts, was selected as the target sample.
3. Results
3.1. Single-variant and gene-based tests in the discovery and joint analyses
In the discovery sample, the single-variant meta-analysis of the
number of drinks per week did not reveal any signiﬁcant associations
(Fig. 1). The top ten SNPs are displayed in Table 1. The lowest p-value
was found for a rare variant in IQSEC1 (MAF=0.005,
p=1.22× 10−6). The second most strongly associated SNP was lo-
cated in AKAP13 (MAF=0.017, p=9.19× 10−6). The gene-based
analysis did not reveal any genes signiﬁcantly associated with alcohol
consumption (Supplementary Fig. 1). The top 10 genes are displayed in
Table 2. Similar to the single variant analysis, IQSEC1 was most
strongly associated with alcohol consumption in the gene-based ana-
lysis (p=8.87× 10−6). Supplementary Table 4 presents the results of
the gene-based analysis for genes previously associated with alcohol
dependence by rare variant studies.
The single-variant analysis of CPD also did not result in any sig-
niﬁcant associations after Bonferroni correction for the number of SNPs
tested (see Table 1 and Fig. 2). The strongest association was found for a
rare variant in HSPG2 (MAF=0.003, p=1.99×10−6). In addition,
we did not identify any genes that were signiﬁcantly associated with
CPD in the gene-based analysis (Supplementary Fig. 2 and Table 2). The
lowest p-value was found for LETMD1 (p=8.68× 10−5). Supple-
mentary Table 4 presents the results of the gene-based analysis for
genes previously associated with nicotine dependence by rare variant
studies.
We subsequently investigated whether the 10 most strongly asso-
ciated variants for alcohol consumption and CPD showed an eﬀect on
alcohol and tobacco use disorders in BioVU. In this cohort, genotype
data on nine alcohol use top SNPs and seven tobacco use top SNPs were
present. When jointly analyzing our meta-analysis associations with
BioVU results, we identiﬁed two genome-wide signiﬁcant SNPs for to-
bacco use (disorder) (Table 3). The two common variants for tobacco
use (disorder) are an exonic and an intronic SNPs located in CHRNA5
and AGPHD, respectively, located at the chromosomal region at
15q25.1. The most signiﬁcant variant was rs16969968 in the gene
CHRNA5 (p=2.39× 10−7).
Fig. 1. Single variant association analysis results of alcohol consumption, A) Manhattan plot, B) quantile-quantile (QQ)-plot.
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3.2. Pathway analyses
The ‘response to ethanol’ and ‘response to nicotine’ pathways from
the GO database (Gene Ontology Consortium, 2015) were not sig-
niﬁcantly involved in alcohol consumption and CPD (p-values of 0.29
and 0.18, respectively).
3.3. Polygenic risk score analysis
We performed PRS analyses to investigate the aggregate contribu-
tion of ExomeChip variants to substance use taking seven of our BBMRI-
NL samples as discovery sample, and the remaining BBMRI-NL sample
(UHP) as target sample. The PRS analyses did not show a signiﬁcant
contribution of rare variants to the phenotypic variance for alcohol
consumption (p=0.124 for PT < 0.02) or CPD (p=0.067 for
PT < 0.45). (Supplementary information section 1 and Supplementary
Figs. 3 and 4).
4. Discussion
The primary aim of this study was to determine the role of rare
genetic variation in alcohol and tobacco use. Conducting a meta-ana-
lysis on ExomeChip data of eight cohorts allowed us to study the role of
rare and low-frequency exonic variants, and in addition a small pool of
common variants, in a large sample. We performed both single-variant
and gene-based tests. Despite our large sample size, we were not able to
identify novel variants or genes that were signiﬁcantly associated with
alcohol consumption or tobacco use in our discovery sample. However,
we identiﬁed several potentially interesting signals that we investigated
for their robustness in an independent sample with data on alcohol and
tobacco use disorders. For tobacco use, the joint analysis of this sample
with our initial meta-analysis showed genome-wide signiﬁcant asso-
ciation for two common genetic variants in the genes AGPHD1 and
CHRNA5, both located at chromosomal region 15q25.1. These genes
belong to the IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK(/AGPHD1)-
PSMA4 gene-cluster that has repeatedly been associated with smoking
severity (Barrie et al., 2017; Liu et al., 2010; Saccone et al., 2010b;
Tobacco and Genetics, 2010). The signiﬁcant non-synonymous variant
rs16969968 in CHRNA5, a gene which encodes for a nicotinic acet-
ylcholine receptor, is the strongest risk variant for nicotine dependence
(Saccone et al., 2010b). AGPHD1 was previously reported to be asso-
ciated with chronic obstructive pulmonary disease (COPD) (Siedlinski
et al., 2013). Our joint analysis of alcohol consumption/alcoholism did
not reveal any signiﬁcant variants.
In addition to the single variant and gene-based analyses, we per-
formed the pathway analysis of two known sets of genes involved in
response to nicotine and ethanol. No signiﬁcant associations were
found, suggesting that if rare variants in these pathways play a role,
their eﬀects are small and the statistical power of our study was
probably not suﬃcient to detect them. The PRS analysis did not show a
signiﬁcant role for ExomeChip variants, meaning that variation in al-
cohol and tobacco use could not be predicted by (primarily) rare and
low-frequency variants. In contrast, previously PRS has been success-
fully used to predict substance use related phenotypes based on
common variants (Vink et al., 2014). Thus, rare exonic variants explain
less phenotypic variation than common variants, although the diﬀer-
ential predictive ability of common and rare variants could also be
explained by insuﬃcient power to estimate eﬀect sizes of rare variants
reliably.
Summarizing, we did not ﬁnd signiﬁcant associations between rare
exonic variants and alcohol and tobacco use. Although somewhat dis-
appointing, it does provide important insight into the genetic archi-
tecture of these traits, as it suggests that these phenotypes are not in-
ﬂuenced by rare variants with large eﬀect sizes. A power analysis
conducted with the Genetic Power Calculator (Purcell et al., 2003;
Visscher et al., 2017) suggests that our discovery samples for alcohol
consumption and CPD had suﬃcient statistical power (> 80%) to de-
tect low-frequency variants (MAF=0.01) with eﬀect sizes of Cohen’s
d≥ 0.37 for alcohol consumption and ≥0.48 for CPD. In contrast, for
the detection of rare variants with a MAF of 0.001, we had suﬃcient
power to detect variants with large eﬀect sizes (i.e., Cohen’s d≥ 1.17
for alcohol consumption and Cohen’s d≥ 1.5 for tobacco use). Al-
though our ﬁndings coupled with the power analysis suggest that rare
genetic variants with large eﬀect sizes do not play an important role, we
cannot rule out the possibility that rare exonic variants with smaller
eﬀects contribute to the phenotypic variation in alcohol consumption
and CPD, as previously suggested by candidate gene studies (Haller
et al., 2012, 2014; Olfson et al., 2016; Thorgeirsson et al., 2016; Xie
et al., 2011; Yang et al., 2015). Even though not all previously reported
rare variants were tagged on the ExomeChip or passed our QC, several
of these variants were included in our analyses, and several of the as-
sociated genes were analyzed with our gene-based tests. Hence, our
observation of the absence of signiﬁcant associations of rare variants
with alcohol consumption or tobacco use, suggests that some of these
rare variants may have been false positive ﬁndings or that the eﬀect
sizes are small. Based on robust ﬁndings from the current study, a study
by Vrieze et al., the above-mentioned candidate gene studies, and the
largest conducted ExomeChip study (investigating adult human height)
to date (Marouli et al., 2017), we estimate that eﬀect sizes up to Cohen’s
d of 0.4 can be expected for rare variants contributing to the phenotypic
variance in alcohol consumption and CPD (Marouli et al., 2017; Vrieze
et al., 2013). This estimate indicates that extremely large sample sizes
would be required for the detection of signiﬁcant rare variant asso-
ciations (Visscher et al., 2017).
Fig. 2. Single variant association analysis results of CPD, A) Manhattan plot, B) quantile-quantile (QQ)-plot.
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We cannot generalize our ﬁndings to other substance use traits as
the power to detect rare genetic variants depends strongly on the ge-
netic architecture of the trait under investigation. For example, rare and
low-frequency variants have been shown to inﬂuence other complex
traits, including height, ADHD, breast cancer, type 2 diabetes, and
schizophrenia (Cheung et al., 2017; Marouli et al., 2017; Richards et al.,
2016; Zayats et al., 2016; Zhou et al., 2017). In some of these studies,
sample sizes were smaller than the sample size in the present study. A
possible explanation is that a larger proportion of the genetic variation
may be attributable to rare variants for diseases that directly aﬀect the
ﬁtness of individuals, because of inherent negative selection on these
variants (Simons and Sella, 2016).
Despite the lack of signiﬁcant ﬁndings, it seems likely that at least
some of our top variants are true associations since the majority of our
top variants showed a consistent direction of eﬀect over the diﬀerent
cohorts that were included. Interestingly, directions of eﬀect were also
fairly consistent in the replication sample in which ICD-9 diagnoses of
alcoholism and tobacco use disorder were obtained. This observation
suggests that quantitative measurements of alcohol and tobacco use and
clinical diagnoses have a shared genetic liability. Furthermore, previous
meta-analyses have combined diﬀerent trait measures into a single
phenotypic trait and generally found high genetic correlations between
the measures (Okbay et al., 2016; Wray and Sullivan, 2017).
The current ﬁndings should be interpreted in view of some key
limitations. The ExomeChip only tags variants located in the exomes of
genes, whereas most GWAS trait-associated hits are located outside
exonic regions (Maurano et al., 2012), suggesting that most trait-asso-
ciated SNPs act through the regulation of gene expression rather than
by altering the protein sequence. It is possible that this characteristic
also holds true for rare variants. Furthermore, the phenotypes measured
in the discovery and the replication sample were not identical, and this
discordance may have reduced the statistical power to detect signiﬁcant
associations in the joint analysis. In addition, most rare variants were
not present in all cohorts of our study, which decreased the statistical
power to detect an eﬀect. Also, the prevalence rates of alcoholism and
tobacco use disorder in BioVU were lower than expected from the
general population (Breslau et al., 2001; Hasin et al., 2007), which may
be explained by misclassiﬁcation among the controls. Diagnosis of
substance use disorders within BioVU is obtained from medical record
data. It is likely that a proportion of the cases (i.e., subjects who meet
criteria for alcoholism or tobacco use disorder) were misclassiﬁed as
controls due to a lack of systematic screening. Furthermore, BioVU is a
hospital-based sample, and it may therefore not be representative of the
general population.
5. Conclusions
We have shown that low-frequency and rare exonic variants do not
have a large impact on inter-individual variability in alcohol and to-
bacco use. Our large sample size allowed us to rule out, with high
conﬁdence, the impact of low-frequency or rare exonic variants with
large eﬀect on these phenotypes. Our ﬁndings conﬁrmed the inﬂuence
of common genetic variants located in the CHRNA5-CHRNA3-CHRNB4
cluster of nicotinic acetylcholine receptor subunit genes on tobacco use.
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